Sarepta Therapeutics (SRPT) Raw Materials (2016 - 2026)

Sarepta Therapeutics has reported Raw Materials for 11 years, with the latest figure at $137.0 million in Q1 2026.

• For the quarter ending Q1 2026, Raw Materials fell 54.19% year-over-year to $137.0 million; the trailing twelve-month figure through Mar 2026 stood at $137.0 million (down 54.19% YoY), and the FY2025 full-year result was $141.3 million, down 49.55% from the prior year.
• Raw Materials for Q1 2026 stood at $137.0 million, down from $141.3 million in the prior quarter.
• The five-year high for Raw Materials was $325.5 million in Q3 2025, with the low at $41.3 million in Q1 2022.
• Average Raw Materials over 5 years is $176.0 million, with a median of $150.0 million recorded in 2024.
• Peak annual rise in Raw Materials reached 523.55% in 2022, while the deepest fall reached 77.86% in 2022.
• Tracing SRPT's Raw Materials over 5 years: stood at $59.2 million in 2022, then soared by 126.36% to $134.0 million in 2023, then surged by 109.05% to $280.0 million in 2024, then slumped by 49.55% to $141.3 million in 2025, then retreated by 3.06% to $137.0 million in 2026.
• The last three Raw Materials figures came in at $137.0 million (Q1 2026), $141.3 million (Q4 2025), and $325.5 million (Q3 2025), per Business Quant data.

Peer Comparison